Purchase this article with an account.
Pearse A. Keane, Florian M. Heussen, Yanling Ouyang, Nils Mokwa, Alexander C. Walsh, Adnan Tufail, Srinivas R. Sadda, Praveen J. Patel; Optical Coherence Tomographic Outcomes In The Avastin (bevacizumab) For Choroidal Neovascularization Trial. Invest. Ophthalmol. Vis. Sci. 2011;52(14):158.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The recent results of the Avastin (Bevacizumab) for Choroidalneovascularization (ABC) Trial provided the first Level I evidencefor the efficacy of bevacizumab in neovascular age-related maculardegeneration (AMD). In this abstract, we analyze the opticalcoherence tomography (OCT) outcomes of the ABC Trial, with theaim of determining differential pharmacodynamic effects andcorrelations with visual acuity.
Data from 122 patients enrolled in the ABC trial, and treatedwith either bevacizumab or the "standard" therapy at the timeof enrollment (pegaptanib, photodynamic therapy (PDT)), wereevaluated. Raw exported StratusOCT images were analyzed - changesin thickness and volume of the neurosensory retina, subretinalfluid (SRF), pigment epithelium detachment (PED), and subretinaltissue, were calculated at week 1 and week 54 post-treatment.OCT-derived parameters were correlated with visual outcomes.
Longitudinal changes in each OCT-derived parameter are summarizedin Figure 1. Correlations between OCT-derived parameters andvisual acuity are summarized in Table 1.
In clinical trials, quantitative OCT subanalysis increases theamount of clinically useful information that can be obtainedfrom OCT images - such information may be useful for highlightingdifferences between treatment and control groups with regardto pharmacodynamics, and in the determination of validated surrogateendpoints.
This PDF is available to Subscribers Only